JP Morgan Maintains Underweight on Y-mAbs Therapeutics, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Tessa Romero maintains an Underweight rating on Y-mAbs Therapeutics (NASDAQ:YMAB) and lowers the price target from $8 to $7.
August 22, 2023 | 2:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan has maintained an Underweight rating on Y-mAbs Therapeutics and lowered the price target from $8 to $7.
The lowered price target by JP Morgan indicates a bearish outlook for Y-mAbs Therapeutics. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100